Novartis Gets OK On $126M Deal To End Drug Delay Claims
Novartis will pay $126 million to end claims brought by a group of direct purchasers accusing the pharmaceutical giant of hatching an illegal deal with Par Pharmaceuticals to delay the release...To view the full article, register now.
Already a subscriber? Click here to view full article